Gynecological cancers as a group comprise approximately 11% of female cancer. 1 In the United States, it is estimated that nearly 80,720 women will be diagnosed in 2009 with gynecological cancers and that approximately 28,120 women will die as a result of these cancers (accounting for 10%of all cancer-related deaths in women). Gynecological cancers are typically diagnosed by history, physical examination, and selected imaging studies. There has been an increasing use of PET using 18 F-fluorodeoxyglucose (FDG) for staging and restaging of these cancers, as well as for assessing response to therapy. .
